BACKGROUND: Ulcerative colitis is characterized by relapsing mucosal inflammation where the lesions include tissue-damaging granulocytes. In addition, T cells and natural killer (NK) cells play important pathophysiologic roles. Chemokines are a large family of peptides that play key roles in the regulation of inflammation. The CXC-chemokines, growth-related oncogene (GRO)-alpha/CXCL1 and interleukin (IL)-8/CXCL8, both recruit neutrophils and possess mitogenic properties, whereas the interferon-dependent CXC-chemokines monokine induced by gamma-interferon (MIG)/CXCL9, interferon-gamma inducible protein of 10 kD/CXCL10, and IFN-inducible T cell alpha chemoattractant/CXCL11 recruit and activate T cells and NK cells. MATERIALS AND METHODS: The expression of CXC-chemokines was studied in eight controls and in 11 patients suffering from ulcerative colitis in the distal part of the colon, before and during topical treatment with corticosteroids. Perfusates (obtained before, after 7 days, and after 28 days of treatment) and pinch biopsies (obtained before and after 28 days of treatment) were collected by colonoscopy. The rectal release of GRO-alpha and MIG was determined by enzyme-linked immunosorbent assay (ELISA), and tissue expression of the chemokines was detected in colonic tissue by immunohistochemistry. RESULTS: In perfusates, high levels of GRO-alpha, IL-8, and MIG were detected compared with controls (p=0.02, 0.005, and p=0.03, respectively). During treatment with corticosteroids, both GRO-alpha and MIG decreased. In clinical nonresponders, characterized by sustained inflammation, the levels of GRO-alpha and MIG remained elevated. Both epithelial cells and granulocytes, present in the submucosa, expressed GRO-alpha and MIG as detected by immunohistochemistry. CONCLUSIONS: CXC-chemokines are likely to be important in the pathophysiology of ulcerative colitis and may become targets for novel treatment strategies. In addition, GRO-alpha may serve as a marker of disease activity.
BACKGROUND:Ulcerative colitis is characterized by relapsing mucosal inflammation where the lesions include tissue-damaging granulocytes. In addition, T cells and natural killer (NK) cells play important pathophysiologic roles. Chemokines are a large family of peptides that play key roles in the regulation of inflammation. The CXC-chemokines, growth-related oncogene (GRO)-alpha/CXCL1 and interleukin (IL)-8/CXCL8, both recruit neutrophils and possess mitogenic properties, whereas the interferon-dependent CXC-chemokines monokine induced by gamma-interferon (MIG)/CXCL9, interferon-gamma inducible protein of 10 kD/CXCL10, and IFN-inducible T cell alpha chemoattractant/CXCL11 recruit and activate T cells and NK cells. MATERIALS AND METHODS: The expression of CXC-chemokines was studied in eight controls and in 11 patients suffering from ulcerative colitis in the distal part of the colon, before and during topical treatment with corticosteroids. Perfusates (obtained before, after 7 days, and after 28 days of treatment) and pinch biopsies (obtained before and after 28 days of treatment) were collected by colonoscopy. The rectal release of GRO-alpha and MIG was determined by enzyme-linked immunosorbent assay (ELISA), and tissue expression of the chemokines was detected in colonic tissue by immunohistochemistry. RESULTS: In perfusates, high levels of GRO-alpha, IL-8, and MIG were detected compared with controls (p=0.02, 0.005, and p=0.03, respectively). During treatment with corticosteroids, both GRO-alpha and MIG decreased. In clinical nonresponders, characterized by sustained inflammation, the levels of GRO-alpha and MIG remained elevated. Both epithelial cells and granulocytes, present in the submucosa, expressed GRO-alpha and MIG as detected by immunohistochemistry. CONCLUSIONS: CXC-chemokines are likely to be important in the pathophysiology of ulcerative colitis and may become targets for novel treatment strategies. In addition, GRO-alpha may serve as a marker of disease activity.
Authors: Patricia L Podolin; Brian J Bolognese; James J Foley; Dulcie B Schmidt; Peter T Buckley; Katherine L Widdowson; Qi Jin; John R White; Judithann M Lee; Richard B Goodman; Tonja R Hagen; Osamu Kajikawa; Lisa A Marshall; Douglas W P Hay; Henry M Sarau Journal: J Immunol Date: 2002-12-01 Impact factor: 5.422
Authors: A Keshavarzian; R D Fusunyan; M Jacyno; D Winship; R P MacDermott; I R Sanderson Journal: Am J Gastroenterol Date: 1999-03 Impact factor: 10.864
Authors: Judong Pan; Marie D Burdick; John A Belperio; Ying Ying Xue; Craig Gerard; Sherven Sharma; Steven M Dubinett; Robert M Strieter Journal: J Immunol Date: 2006-02-01 Impact factor: 5.422
Authors: Arne Egesten; Mette Eliasson; Helena M Johansson; Anders I Olin; Matthias Morgelin; Anja Mueller; James E Pease; Inga-Maria Frick; Lars Bjorck Journal: J Infect Dis Date: 2007-01-18 Impact factor: 5.226
Authors: Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Kendra L Puig; Adam J Swigost; Xudong Zhou; Mary Ann Sens; Colin K Combs Journal: J Neuroimmune Pharmacol Date: 2011-11-29 Impact factor: 4.147
Authors: Joseph B McPhee; Cherrie L Small; Sarah A Reid-Yu; John R Brannon; Hervé Le Moual; Brian K Coombes Journal: Infect Immun Date: 2014-05-27 Impact factor: 3.441
Authors: Sureshkumar Muthupalani; Zhongming Ge; Yan Feng; Barry Rickman; Melissa Mobley; Amanda McCabe; Nico Van Rooijen; James G Fox Journal: Infect Immun Date: 2012-10-01 Impact factor: 3.441
Authors: T Jakobsson; L-L Vedin; T Hassan; N Venteclef; D Greco; M D'Amato; E Treuter; J-Å Gustafsson; K R Steffensen Journal: Mucosal Immunol Date: 2014-05-07 Impact factor: 7.313
Authors: Richard Ahrens; Amanda Waddell; Luqman Seidu; Carine Blanchard; Rebecca Carey; Elizabeth Forbes; Maria Lampinen; Tara Wilson; Elizabeth Cohen; Keith Stringer; Edgar Ballard; Ariel Munitz; Huan Xu; Nancy Lee; James J Lee; Marc E Rothenberg; Lee Denson; Simon P Hogan Journal: J Immunol Date: 2008-11-15 Impact factor: 5.422